Last reviewed · How we verify
insulin glulisine, insulin aspart
At a glance
| Generic name | insulin glulisine, insulin aspart |
|---|---|
| Also known as | Apidra, NovoRapid |
| Sponsor | Profil Institut für Stoffwechselforschung GmbH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Upper respiratory tract infection
- Nasopharyngitis
- Upset stomach
- Skin irritation, welt
Key clinical trials
- The Impact of Two Different Insulin Dose Calculation on Postprandial Glycemia After Mixed Meal. (PHASE4)
- Afrezza® INHALE-1 Study in Pediatrics (PHASE3)
- Closed Loop From Onset in Type 1 Diabetes (NA)
- Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes (PHASE3)
- FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR) (PHASE4)
- Super-Bolus: Effects on Postprandial Glycemia After High Glycemic Index Meal (PHASE4)
- The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children (PHASE4)
- Efficacy and Safety of Android Artificial Pancreas System in Adult Patients With Type 1 Diabetes Mellitus in China (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: